Coronary heart disease and genetic variants with low phospholipase A2 activity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  New England Journal of Medicine

• Publication date

  2015-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMc1409673PMID 25587968PMCID PMC4339029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Darapladib for preventing ischemic events in stable coronary heart disease.

  2014cited by this paper
• A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

  2014cited by this paper
• Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

  2010cited by this paper
• Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability.

  2009cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper

• Pharmacogenomics-based systematic review of coronary artery disease based on personalized medicine procedure

  2024cites this paper
• Sleep Disordered Breathing, Obesity and Atrial Fibrillation: A Mendelian Randomisation Study

  2022cites this paper
• Genetics of coronary artery disease in the post‐GWAS era

  2021cites this paper
• Frequent Daytime Napping is Detrimental to Human Health: A phenotype-wide Mendelian Randomization Study

  2020cites this paper
• Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants

  2020cites this paper
• On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management

  2020cites this paper
• Lipoprotein‐associated phospholipase A2: The story continues

  2019cites this paper
• Detecting Clustered Independent Rare Variant Associations Using Genetic Algorithms

  2019cites this paper
• Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations

  2019cites this paper
• Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval

  2018cites this paper
• Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC).

  2018cites this paper
• From lipid locus to drug target through human genomics.

  2018cites this paper
• Precision Medicine for Prosthetic Valve Deterioration: A Glimpse Into the Future?

  2018cites this paper
• Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease

  2018cites this paper
• Novel and Emerging Biomarkers with Risk Predictive Utility for Atherosclerotic Cardiovascular Disease

  2018cites this paper
• Genetic risk factors of cardiovascular disease

  2018cites this paper
• Precision Medicine for Prosthetic Valve Deterioration A Glimpse Into the Future?*

  2018cites this paper
• Applications of nuclear magnetic resonance in lipid analyses: An emerging powerful tool for lipidomics studies.

  2017cites this paper
• Recent Developments in Mendelian Randomization Studies

  2017cites this paper
• Mendelian randomization analyses in cardiometabolic disease: challenges in evaluating causality

  2017cites this paper
• Leveraging human genetics to guide drug target discovery.

  2017cites this paper
• Genetics of coronary artery disease: discovery, biology and clinical translation

  2017cites this paper
• Mendelian randomization in cardiometabolic disease: challenges in evaluating causality

  2017cites this paper
• Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity

  2017influential citation
• Immune-mediated mechanisms of atherosclerosis and implications for the clinic

  2016cites this paper
• A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults

  2016cites this paper
• Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.

  2016cites this paper
• Using Mendelian Randomization Studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine

  2016cites this paper
• Genetics—Current and Future Role in the Prevention and Management of Coronary Artery Disease

  2016cites this paper
• [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].

  2016cites this paper
• Lipoprotein associated Phospholipase A 2 Activity, Apolipoprotein C3 Loss-of-function Variants and Cardiovascular Disease: The Atherosclerosis Risk In Communities Study

  2016cites this paper
• Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

  2016cites this paper
• A Causal Network Analysis of the Fatty Acid Metabolome in African-Americans Reveals a Critical Role for Palmitoleate and Margarate

  2016cites this paper
• Genetic analysis of emerging risk factors in coronary artery disease.

  2016cites this paper
• Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China

  2016cites this paper
• STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases

  2015cites this paper
• Enzymatic Targets in Atherosclerosis

  2015cites this paper
• Oxidant/antioxidant status, paraoxonase activity, and lipid profile in plasma of ovariectomized rats under the influence of estrogen, estrogen combined with progesterone, and genistein

  2015cites this paper
• Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.

  2015cites this paper
• Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease

  2015cites this paper